IL22 and colitis: In addition to MI-2 restoring the gut immune homeostasis with host immune modulating capacity by reducing inflammatory cytokines (TNF-α, IL-1β, IL-17α, and IL-22), restoration of healthy intestinal microbiome in MI-2-treated mice with DSS-induced colitis may be considered therapeutic for ulcerative colitis.